Syndromic incidence of ovarian cancer after liver transplantation: Is breast cancer an antecedent risk?

Liver Transplantation

Volumn 10, Issue 1, 2004, Pages 156-157

  Buell, Joseph F ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ANAMNESIS; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; CARCINOGENESIS; ENDOMETRIUM CANCER; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; HEREDITY; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; LIVER TRANSPLANTATION; MALE; MORTALITY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; UTERINE CERVIX CANCER;

EID: 3042853027     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20026     Document Type: Article

References (12)

1. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000;7:147-156.
2. Penn I. Post-transplant malignancy: The role of immunosuppression. Drug Saf 2000;23:101-113.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998;23:147-148
4. Yarchoan R, Little RF. Immunosuppression-related malignancies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:2575-2996.
5. Boardman RE, Gross TG, Hanaway MJ, First MR, Trofe J, Alloway RR, Beebe TM, Woodle ES, Buell JF. De novo ovarian cancer post solid organ transplantation. Am J Transplant 2003; 3:188.
6. Molmenti EP, Molmenti H, Weinstein J, Elliott EE, Fasola CG, Orr D, et al. Syndromic incidence of ovarian carcinoma after liver transplantation, with special reference to anteceding breast cancer. Dig Dis and Sci 2003;48:187-189.
7. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, et al. De Novo tumors after liver transplantation: A single-institution experience. Liver Transpl 2002;8:285-291.
8. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:1597-1632.
9. Yakupoglu YK, Knight RJ, Katz SM, Van Buren CT, Buell JF, Woodle ES, et al. Low incidence of malignancy among sirolimus-cyclosporine treated transplant recipients. Am J Transplant. In press.
10. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LM, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: A multiethnic case-control study. Am J Epidemiol 2003;158:629-638.
11. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant 2002(1 suppl 2):1-95.
12. Amare D, Buell JF. Management of malignancy after renal transplantation. The Transplant Nephrology Community Outreach Program at the University of Alabama School of Medicine. April 2003.